mivazerol profile

mivazerol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	60784
CHEMBL ID	2105189
SCHEMBL ID	593707
SCHEMBL ID	8097939
MeSH ID	M0232871

Synonym
mivazerol
mivazerolum [inn-latin]
mivazerol [inn]
alpha-imidazol-4-yl-2,3-cresotamide
2-hydroxy-3-(1h-imidazol-5-ylmethyl)benzamide
L001373
125472-02-8
mivazerolum
unii-w5p1ssa8kd
w5p1ssa8kd ,
2-hydroxy-3-(1h-imidazol-4-ylmethyl)-benzamide
CHEMBL2105189
.alpha.-imidazol-4-yl-2,3-cresotamide
mivazerol [mi]
mivazerol [mart.]
SCHEMBL593707
SCHEMBL8097939
1,2,3,4-butanetetracarboxylicacid
DTXSID30154782
3-((1h-imidazol-4-yl)methyl)-2-hydroxybenzamide
benzamide, 2-hydroxy-3-(1h-imidazol-4-ylmethyl)-
A926791
FT-0752041
2-hydroxy-3-(1h-imidazol-4-ylmethyl)benzamide
Q6593932

Research Excerpts

Overview

Mivazerol is an alpha 2-adrenoceptor agonist designed to prevent adverse cardiac outcome in perioperative patients. The drug has demonstrated anti-ischemic effects, both in animals and in patients with myocardial ischemia.

Excerpt	Reference	Relevance
"Mivazerol is an imidazole derivative with agonist properties at the alpha 2-adrenoceptor and appears to be an effective antianginal."	( Exercise tolerance in angina is improved by mivazerol--an alpha 2-adrenoceptor agonist. Decroly, P; Kharkevitch, T; Oliver, MF; Wright, RA, 1993)	1.27
"Mivazerol is a new and selective alpha 2-adrenoceptor agonist which has demonstrated anti-ischemic effects, both in animals and in patients with myocardial ischemia. "	( Effects of immobilization stress on hippocampal monoamine release: modification by mivazerol, a new alpha 2-adrenoceptor agonist. Hanin, I; Kindel, GH; Wülfert, E; Zhang, X, 1995)	1.96
"Mivazerol is a new compound that could potentially reduce perioperative cardiovascular morbidity and mortality in patients with or at risk of coronary disease and submitted to surgery. "	( Peripheral alpha 2-adrenoceptor-mediated sympathoinhibitory effects of mivazerol. Giudicelli, JF; Gobert, J; Noyer, M; Richer, C; Wülfert, E, 1996)	1.97
"Mivazerol hydrochloride is a new alpha 2-adrenoceptor agonist. "	( Perioperative sympatholysis. Beneficial effects of the alpha 2-adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. McSPI--Europe Research Group. , 1997)	1.96
"Mivazerol is a new and selective alpha 2-adrenoceptor agonist, devoid of hypotensive effects, which has been designed to prevent adverse cardiac outcome in perioperative patients with, or at risk coronary artery disease."	( Mivazerol, a new alpha 2-adrenergic agonist, blunts cardiovascular effects following surgical stress in pentobarbital-anesthetized rats. Hanin, I; Wülfert, E; Zhang, X, 1997)	3.18
"Mivazerol (MIV) is an alpha 2-adrenoceptor agonist designed to prevent adverse cardiac outcome in perioperative patients. "	( Mivazerol prevents the tachycardia caused by emergence from halothane anesthesia partly through activation of spinal alpha 2-adrenoceptors. Gobert, J; Guyaux, M; Noyer, M; Vandevelde, M; Wülfert, E, 1998)	3.19
"Mivazerol is a new and selective alpha 2-adrenergic receptor agonist devoid of hypotensive effects (1, 2). "	( Mivazerol inhibits intrathecal release of glutamate evoked by halothane withdrawal in rats. Hanin, I; Kindel, G; Wülfert, E; Zhang, X, 1998)	3.19
"Mivazerol is a drug with alpha2-agonist properties that reduces post-ganglionic noradrenaline availability and spinal efferent sympathetic output."	( Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Goldman, L; Holme, I; Julian, DG; Oliver, MF, 1999)	2.15

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	20 (66.67)	18.2507
2000's	9 (30.00)	29.6817
2010's	1 (3.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (16.13%)	5.53%
Reviews	6 (19.35%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	20 (64.52%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	1.98	1	0	catechols; dihydroxyphenylacetic acid	human metabolite
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	1.99	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
homovanillic acid Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.	1.98	1	0	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	3.5	2	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	3.1	1	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
cirazoline cirazoline: posseses agonist properties at alpha-adrenoreceptor sites; RN given refers to parent cpd	1.99	1	0	aromatic ether
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	8.58	12	1	clonidine; imidazoline
halothane [no description available]	2.4	2	0	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
alpha-methylhistamine alpha-methylhistamine: a histamine H3 receptor agonist; RN given refers to parent cpd without isomeric designation. alpha-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the alpha-position.	2	1	0	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.4	2	0	barbiturates	GABAA receptor agonist
corticosterone [no description available]	2.05	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.4	2	0	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2.68	3	0	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	1.99	1	0	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	2.4	2	0	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.68	3	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
medetomidine Medetomidine: An agonist of RECEPTORS, ADRENERGIC ALPHA-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of DEXMEDETOMIDINE.	1.99	1	0	imidazoles
rx 821002 2-methoxyidazoxan: 2-methoxy analog of idazoxan. 2-methoxyidazoxan : A benzodioxine that is idazoxan substituted at position 2 by a methoxy group.	1.98	1	0	benzodioxine; cyclic ketal; imidazolines	alpha-adrenergic antagonist
dexmedetomidine [no description available]	6.77	6	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative

Condition	Relationship Strength	Studies	Trials
Apoplexy [description not available]	4.01	1	0
Cardiac Diseases [description not available]	4.8	2	0
Complication, Intraoperative [description not available]	7.38	5	1
Cardiovascular Stroke [description not available]	4.77	2	0
Complication, Postoperative [description not available]	8.22	7	2
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	4.8	2	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	4.77	2	0
Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.	8.22	7	2
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	4.01	1	0
Heart Disease, Ischemic [description not available]	7.19	8	3
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	12.19	8	3
Bacterial Disease [description not available]	2.05	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.73	3	0
Hypothermia, Accidental [description not available]	2.42	2	0
Bacterial Infections Infections by bacteria, general or unspecified.	2.05	1	0
Hypothermia Lower than normal body temperature, especially in warm-blooded animals.	7.42	2	0
Arrhythmia [description not available]	2.93	1	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2.93	1	0
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	4.77	7	0
Anterior Circulation Transient Ischemic Attack [description not available]	2.44	2	0
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.44	2	0
Angor Pectoris [description not available]	4.34	2	2
Angina Pectoris The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.	4.34	2	2
Coronary Heart Disease [description not available]	8.78	2	1
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	3.78	2	1
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	1.99	1	0
Anoxemia [description not available]	1.99	1	0
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	1.99	1	0
Tachyarrhythmia [description not available]	2.4	2	0
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	7.4	2	0
Decerebrate Posturing [description not available]	1.99	1	0
Drug Withdrawal Symptoms [description not available]	1.99	1	0
Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.	1.99	1	0
Injury, Myocardial Reperfusion [description not available]	2	1	0
Ventricular Fibrillation A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	2	1	0
Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.	3.39	1	1
Benign Neoplasms [description not available]	2.92	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.92	1	0

mivazerol

Description

Cross-References

Synonyms (25)

Research Excerpts

Overview

Research

Studies (30)

Market Indicators

Research Demand Index: 22.14

Study Types

mivazerol

Description

Cross-References

Synonyms (25)

Research Excerpts

Overview

Research

Studies (30)

Market Indicators

Research Demand Index: 22.14

Study Types

Related Drugs (19)

Related Conditions (38)